Multidol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Multidol

Quick Facts

Property Description
Active ingredient Ibuprofen
Form Tablets, capsules, oral suspension, syrup
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Systemic relief of pain, fever, and inflammation
Origin Synthetic, propionic acid derivative

What is Multidol?

What Type of Drug is Multidol?

Multidol is a pharmaceutical preparation with the active component Ibuprofen, a substance chemically identified as a propionic acid derivative. This medication is classified within the major pharmacological group of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), a designation widely recognized by international health authorities. Ibuprofen is a synthetic compound. Multidol is often available in specific liquid forms, such as syrup and oral suspension, making it a key option for precise dosing and easier administration across different patient demographics, including children.

Composition, Origin, and Available Forms

Multidol is a single-ingredient product, containing only the active substance Ibuprofen, a compound that exists as a racemic mixture of two mirror-image molecules (S- and R-enantiomers). Pharmacological studies have consistently supported the efficacy of the NSAID class in managing inflammatory conditions. The medication is formulated for oral administration in various presentations, including solid forms (tablets, capsules, caplets) and liquid forms, which combine the active substance with appropriate pharmaceutical excipients or an aqueous base/vehicle.

General Purpose: Relief from Pain, Inflammation, and Fever

The general purpose of Multidol is to provide systemic relief by addressing the primary symptoms driven by inflammation. Its classification as an NSAID directly links its therapeutic goal to the management of mild to moderate pain, the reduction of fever, and the alleviation of general inflammatory discomfort. Research confirms that Ibuprofen is a crucial tool for managing these common ailments globally. The medication offers a unified approach by focusing on the underlying pathways that mediate the body’s inflammatory response.

Regulatory References

  1. Ibuprofen Drug Information (MedlinePlus)
  2. Ibuprofen - StatPearls (NCBI/NIH)
  3. Ibuprofen on WHO Electronic Essential Medicines List (eEML)

What side effects are possible with Multidol?

Possible Side Effects and Safety Information

The safety profile of Multidol, which contains Ibuprofen, is defined by adverse reactions classified by official regulatory documents based on frequency and effect on physiological systems. As a Nonsteroidal Anti-inflammatory Drug (NSAID), its safety data emphasizes the risk profile across several System-Organ Classes.


Adverse Reaction Classification

Side effects are categorized by regulatory authorities into frequency tiers:

  • Common reactions (affecting up to 1 in 10 individuals) primarily involve Gastrointestinal disorders (e.g., dyspepsia, abdominal pain, nausea) and Nervous system disorders (e.g., headache, dizziness).
  • Uncommon reactions include gastrointestinal ulceration, bleeding, and hypersensitivity responses such as rash.
  • Rare and Very Rare reactions are also documented, involving systems like the Hepato-biliary disorders and Blood and lymphatic system disorders.

Serious Adverse Reactions and Safety Patterns

The regulatory label includes prominent information regarding the risk of serious adverse reactions. These include severe cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal events (bleeding, ulceration, and perforation). The official safety data notes that the risk of both serious cardiovascular and gastrointestinal events is linked to duration of use and cumulative dose.

Safety information also highlights specific constraints for certain populations. Older adults are identified as having a greater risk for serious gastrointestinal adverse events. Use is generally contraindicated in individuals with severe heart failure, severe renal failure, or severe hepatic failure, as defined by official regulatory texts.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

An overdose of Multidol (Ibuprofen) may result in a documented spectrum of clinical manifestations, primarily involving the gastrointestinal and central nervous systems. Initial signs often include nausea, vomiting, epigastric pain, headache, dizziness, drowsiness, and sensory disturbances such as tinnitus.

Regulatory labeling specifies that overdose can progress to severe systemic outcomes. These may involve serious complications such as metabolic acidosis, acute renal failure, and severe hypotension. Neurological deterioration, including seizures and coma, is also officially documented, particularly following massive ingestion or in susceptible populations. The regulatory profile notes that the elderly are at increased risk for serious consequences following overdose.

Required Emergency Action

The official guidance strictly mandates that immediate medical attention must be sought following a suspected overdose, even if initial symptoms are absent or mild. Individuals should contact emergency services or a poison control center for guidance.

Regulatory documents specify that no specific antidote is known for Ibuprofen overdose. Management is described as primarily symptomatic and supportive, focusing on maintaining vital functions and correcting fluid, electrolyte, and acid-base abnormalities. Hospital monitoring, including observation of vital signs and laboratory parameters, is a required measure in managing overdose cases.

Therapeutic Uses of Multidol

What Multidol Treats: Main Uses and Benefits

Multidol is commonly used across conditions presenting with systemic or localized discomfort and is applied across domains where additional symptomatic support is needed for pain relief, fever reduction, and the management of inflammatory symptoms. The medication is considered relevant for symptomatic support in these conditions. It supports the patient during difficult episodes by easing distress and contributes to improved comfort across many conditions.

The medication is commonly used to help manage symptoms associated with headaches, toothaches, muscle aches, migraines, primary dysmenorrhea (menstrual pain), and musculoskeletal stiffness tied to osteoarthritis and rheumatoid arthritis.

“The medication is considered relevant to help address symptom clusters that may become intense or disruptive, offering supportive relief in acute and episodic situations.”


Quick Fact: Relief for Episodic Discomfort

Symptom Domain Conditions Managed (General) Patient Benefit
Pain and Fever Acute viral illness (colds, flu), dental pain Helps maintain a sense of stability when symptoms are noticeable
Inflammation Sprains, strains, chronic arthritis flare-ups May assist with maintaining comfort and function

Eligibility and Restrictions for Use

Eligibility for Multidol Use

Multidol (Ibuprofen) eligibility is defined by official regulatory documentation, outlining specific populations for permitted, restricted, or prohibited use.

Classification Eligibility Status (As per Labeling)
Allowed Populations Adults and adolescents over 12 years of age. Children ge 6 months for specific formulations. Lactating women are generally eligible.
Use Not Established Safety and effectiveness have generally not been established for infants under six months of age.

Contraindicated Populations (Must Not Use)

Multidol is contraindicated and must not be used by patients who fall into the following officially documented categories:

  • A history of hypersensitivity or allergic reactions to Ibuprofen, Aspirin, or other NSAIDs.
  • Active or a history of recurrent peptic ulcer or gastrointestinal hemorrhage (bleeding).
  • Severe heart failure (NYHA Class IV), severe hepatic failure, or severe renal failure.
  • The third trimester of pregnancy (after 28 weeks, or 20 weeks per updated FDA guidance).
  • Setting of Coronary Artery Bypass Graft (CABG) surgery.

Restricted and Conditional Use

Use is allowed but requires special consideration and often reduced duration or dose for the following groups:

  • Older Adults (Geriatric): Use requires conditional restriction due to increased risk of adverse reactions, requiring the lowest effective dose.
  • Cardiovascular Conditions: High doses (e.g., 2400 mg/day) should be avoided in patients with established cardiovascular disease or uncontrolled hypertension.
  • Mild to Moderate Organ Impairment: Patients with mild to moderate kidney or liver dysfunction are eligible but must use caution.
  • Pregnancy (First and Second Trimesters): Use is only permitted if the potential benefit justifies the risk to the fetus.

What should I know about interactions with other medicines?

The regulatory profile for Multidol (Ibuprofen) defines specific interaction patterns based on documented pharmacokinetic and pharmacodynamic mechanisms.

Interaction-Related Restrictions

Co-administration is restricted with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and COX-2 selective inhibitors due to a documented increase in the risk of serious gastrointestinal (GI) adverse events. Combinations with high-dose Aspirin (above 75 mg daily) are also generally restricted.

Pharmacodynamic Interactions

A major concern is the enhanced risk of bleeding, documented when Multidol is co-administered with Anticoagulants, Anti-platelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs), and Oral Corticosteroids.

Multidol may reduce the therapeutic effect of Anti-hypertensives and Diuretics. The concurrent use of Diuretics, ACE inhibitors, and Ibuprofen is noted for the heightened risk of renal impairment, particularly in elderly patients.

Pharmacokinetic and Timing Rules

Multidol may cause decreased renal clearance and increased plasma concentrations of agents such as Lithium, Methotrexate, and Cardiac Glycosides.

For patients taking low-dose Aspirin, regulatory guidance specifies a timing separation to preserve the anti-platelet effect: Ibuprofen must be administered at least eight hours before or 30 minutes after the immediate-release Aspirin dose. Daily consumption of three or more alcoholic drinks is documented to increase the risk of severe stomach bleeding.

Mechanism of Action

How Multidol Works

Multidol exerts its action through distinct molecular mechanisms that influence key signaling pathways at multiple physiological levels.


Modulation of Specific Receptor Signaling

Multidol acts within domains involving receptor- or enzyme-mediated signaling to modify early molecular steps. This action initiates or suppresses signaling sequences that modify mediator activity, resulting in altered pathway flux.


Targeted Regulation of Dysregulated Systems

The drug is relevant in systems where specific transmitters or mediators dominate, engaging mechanisms that regulate overactive or dysregulated processes. By modifying these processes, Multidol modulates the feedback loop that governs physiological responses and influences pathway activity that may increase under specific conditions.


Influence on Intracellular Signaling Cascades

Multidol modulates key pathways associated with physiological responses by operating in cascades where multiple layers of pathway activation occur. This mechanism influences feedback regulation, influencing subsequent physiological outputs.

Dosage and Administration Information

How Multidol is Used: Official Administration Guidelines

Multidol (Ibuprofen) is administered according to a highly regulated framework that defines the route, dosage, frequency, and preparation requirements based on official labeling. The medication is primarily intended for oral administration, available in solid forms (tablets, capsules) and liquid forms (suspensions, syrup). For specialized care and when the oral route is not feasible, an intravenous (IV) solution is an approved alternative for administration by qualified professionals.


Standard Dosing and Frequency

The usage pattern depends on the intended duration of treatment. For acute, short-term use (such as for pain or fever), a typical single adult dose is 200 mg or 400 mg, taken every 4 to 6 hours as needed. For the management of chronic conditions, such as inflammatory arthritis, the total daily dose generally ranges from 1200 mg to 3200 mg and is divided into three or four doses over the 24-hour period. The maximum approved dose for prescription use in adults is 3200 mg per day.


Administration Requirements and Adjustments

Liquid oral forms, such as suspension or syrup, require the product to be shaken well prior to use, and the dose must be measured using a calibrated device to ensure precision. Solid oral forms may be taken with food or milk to help mitigate gastrointestinal discomfort. For pediatric patients (aged 6 months to 12 years), the dose is not fixed but is calculated based on the child's body weight (typically 5 mg/kg to 10 mg/kg per dose), with specific limits on the total daily intake. In cases where a dose is missed, regulatory guidance advises taking it when remembered, unless it is close to the next scheduled dose, in which case the missed dose is skipped to prevent doubling. The maximum duration for non-prescription self-use is limited to 10 days for pain or 3 days for fever.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Multidol

Evidence for Use in Acute Pain and Related Conditions

Research exploring Multidol in studies focused on physical discomfort has primarily relied on short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined how symptoms change over time and monitored outcomes such as pain intensity and the need for additional medication. Findings described patterns observed over short time intervals to assess changes in episodic or acute symptom patterns. Research has explored the relationship between different doses, and the data show patterns related to a point where increasing the dose beyond a certain threshold was not associated with a greater observed change in measured outcome. What remains uncertain is the pattern of pain lasting beyond the immediate study period, as follow-up durations were limited in most key studies.


Evidence for Use in Fever and Antipyresis

The research for Multidol’s role in fever is based on controlled trials and meta-analyses that explored temporary physiological imbalance. These studies monitored outcomes related to systemic or functional imbalance, specifically focusing on measured body temperature in the pediatric group (children under 18). While studies report short-term measurements, evidence is limited regarding the use and observed response in frail older adults experiencing fever. Research provides limited insight into the long-term outcomes of fever studies on broader health metrics.


Evidence for Use in Chronic Inflammatory Conditions

Research evaluated Multidol for chronic inflammatory conditions (e.g., Osteoarthritis and Rheumatoid Arthritis) using Randomized Controlled Trials and observational follow-up studies. These studies monitored changes in outcomes related to physical discomfort and functional metrics over periods ranging from several weeks to a year. Comparative studies monitored differences in measured outcomes between Multidol and other similar compounds, and findings were mixed, suggesting measured changes were often not significantly different among various non-selective NSAIDs studied. Evidence quality varies across studies, and research provides limited insight into the compound’s direct long-term relationship with the progression of underlying inflammatory processes.


Evidence in Special Populations and Research Gaps

Multidol was studied for use in distinct patient groups, and the evidence landscape for children and adolescents has been widely explored in studies for fever and acute pain. However, data for certain groups remain insufficient, with limited information for long-term outcomes specific to subgroups of older adults. The research highlights what is still uncertain: data are still emerging for certain specific subgroups, and the certainty remains low for questions regarding the full profile of long-term outcomes. The current evidence base does not determine whether an individual will respond similarly, as findings describe group patterns.

Key Studies & References WHO Model List of Essential Medicines (Ibuprofen entry)

Frequently Asked Questions (FAQ)

Common questions about Multidol (FAQ)

Q: How quickly can a person expect to feel the effects of Multidol?

A: Official information indicates that Multidol is well absorbed after it is taken. Clinical studies often observe the effects, such as relief from discomfort, within a relatively short time interval following administration.

Q: How long does the effect of one dose of Multidol usually last?

A: The duration of the drug's effect is typically related to its half-life, which is roughly 1.9 to 2.2 hours. Because of this, standard dosing recommendations often refer to intervals of 4 to 6 hours.

Q: Are there any common foods or drinks that should be avoided while using Multidol?

A: Official documentation notes that the use of alcohol is linked to an increased risk of serious gastrointestinal bleeding. No other specific common foods or drinks are explicitly restricted in the primary warnings.

Q: What is the difference between Multidol and similar treatments I see advertised?

A: Multidol’s active ingredient, ibuprofen, is chemically defined as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification means it works by inhibiting the body's production of prostaglandins, which are key chemical messengers in the process of pain and inflammation. This mechanism of action differentiates it from other classes of pain relievers, such as acetaminophen.

Q: Is it true that Multidol is not suitable for people with certain kidney issues?

A: Multidol is strictly contraindicated in patients with severe renal failure. Use in individuals with existing or chronic kidney conditions requires caution and special consideration, as official documents note a potential increased risk of adverse renal events, particularly with prolonged use.

Q: Will Multidol make me feel drowsy or affect my ability to drive?

A: Common reported side effects in official documents include headache and dizziness. Because some individuals may experience these effects, official labeling documents that awareness is important before operating machinery or driving.

Q: Do older adults typically require a different consideration for Multidol use?

A: Yes, older adults (geriatric) are specifically identified in official documents as a population requiring conditional use. This is due to a documented greater risk for serious gastrointestinal and cardiovascular adverse events compared to younger adults, which means special consideration is needed for dosage.

Q: Can Multidol affect the results of standard lab blood tests?

A: Official information suggests Multidol may affect certain laboratory tests, such as those used to monitor kidney function or bleeding time.

Q: Is Multidol safe to use if I have high blood pressure?

A: Patients with established or uncontrolled hypertension (high blood pressure) are advised that use of Multidol requires caution. Official product warnings recommend that high doses (e.g., 2400 mg/day or more) should generally be avoided in patients who have established cardiovascular disease.

Q: Is Multidol available as a generic version?

A: Yes. The active ingredient in Multidol, Ibuprofen, is a commonly available, widely marketed generic compound that has been approved by regulatory bodies globally.

Q: Is Multidol a type of narcotic or opioid medication?

A: No. Multidol is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is chemically and pharmacologically distinct from narcotic (opioid) medications.

Q: Does the time of day matter when taking Multidol?

A: While the core labeling focuses on dosing intervals, specific formulations are available that combine the active ingredient with another ingredient for use at nighttime to help with acute pain and sleeplessness. For chronic use, taking it at the same time daily helps with consistency.

Q: What happens if I miss a scheduled dose of Multidol?

A: Official regulatory guidance advises taking a missed dose when remembered, unless that time is close to the time of the next scheduled dose. In that case, regulatory guidance advises skipping the missed dose in this situation to prevent the risk of doubling the intake.

Q: Is Multidol known to cause stomach upset?

A: Yes. Gastrointestinal disorders such as dyspepsia (indigestion) and stomach upset are listed among the most common reported reactions in official documents. Taking Multidol with food or milk may help to mitigate this discomfort.

Q: If I switch from another drug, how long should I wait before starting Multidol?

A: Regulatory guidance notes that for patients taking low-dose Aspirin, Multidol should be administered at least eight hours before or 30 minutes after the immediate-release Aspirin dose to maintain Aspirin's anti-platelet effect. Restrictions also apply when switching from other NSAIDs.

Q: Are there any reported interactions between Multidol and herbal remedies?

A: Official documentation states the importance of discussing all other medications, including vitamins and herbal remedies, with a health professional before use. While specific warnings for herbal remedies are not standardized across all labels, this caution is intended to manage potential unknown interactions.

Q: Does taking Multidol at the same time every day improve the outcome?

A: For individuals taking Multidol on a regular basis for chronic conditions, taking it at the same time every day is described in regulatory documents as a standard approach for maintaining consistent dosing.

Q: Is there a maximum time someone can safely use Multidol?

A: For non-prescription self-use, the maximum duration is officially limited to 10 days for pain or 3 days for fever. For prescription use, the duration is determined by a health professional, and official guidelines suggest the need for long-term use should be periodically evaluated.

Q: What is the purpose of the inactive ingredients in Multidol tablets?

A: The inactive ingredients (excipients) are necessary for the product's formulation. They serve critical roles such as giving the tablet its physical structure, helping to control the drug's release rate, and providing the color or coating.

Q: Is Multidol known to affect sleep patterns?

A: Multidol is generally used to relieve symptoms like pain and fever, which often interfere with sleep. Some specific formulations containing the active ingredient are available that are intended to support the relief of acute nighttime pain and accompanying sleeplessness.

Q: Can someone who is vegetarian or vegan use Multidol?

A: The use of Multidol by vegetarians or vegans depends on the specific formulation, as inactive ingredients vary. The official list of inactive ingredients often includes plant-derived components like cellulose and starches. The specific inclusion of animal-derived components, like gelatin in some capsules, varies by product formulation.

Q: What kind of warnings are included on the prescription label for Multidol?

A: Official labeling from regulatory agencies includes prominent warnings regarding the risk of serious cardiovascular thrombotic events (such as heart attack or stroke) and serious gastrointestinal events (such as bleeding, ulceration, or perforation). These risks are typically associated with higher doses and long-term use.

Q: Do studies show a difference in effect based on age or gender?

A: Official research summaries note that while the evidence landscape has been widely explored for children, data remains insufficient for long-term outcomes specific to subgroups of older adults. The research findings generally describe group patterns and do not provide predictability for an individual's response based on age or gender.

Q: Can Multidol be taken with common cold and flu medicines?

A: Official warnings state that Multidol is contraindicated for concurrent use with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Many common over-the-counter cold and flu preparations contain NSAIDs as active ingredients, and combining these products can lead to a heightened risk of serious adverse events.

Q: What does 'Multidol is generally well-tolerated' mean in official documents?

A: This term indicates that the majority of individuals who use the drug experience no adverse reactions or only common, non-serious reactions, such as mild headache or temporary gastrointestinal upset, as documented in clinical trials.

Q: Does taking Multidol affect fertility?

A: Official information notes that Multidol and other NSAIDs can potentially affect female fertility by temporarily inhibiting ovulation, an effect that is documented to be reversible after the drug is discontinued.

Q: What kind of patient populations were included in the primary studies for Multidol?

A: Primary studies have extensively explored the use of Multidol in children and adolescents for acute pain and fever, as well as in a broad range of adults for acute pain and chronic inflammatory conditions like Osteoarthritis and Rheumatoid Arthritis.

Q: Is it necessary to have routine blood tests while taking Multidol?

A: For patients receiving long-term therapy with Multidol, official guidance states that individuals are advised to be periodically reviewed by a health professional. This review may involve routine blood tests to check for potential adverse effects or the development of cardiovascular risk factors.

Q: If I feel better, should I continue using Multidol as prescribed?

A: If the drug was prescribed by a health professional, the medication’s use is governed by the length of therapy defined by the prescriber. Any change to the prescribed regimen should be discussed with a health professional.

Q: Does the form of the drug (tablet, capsule, liquid) affect how quickly Multidol works?

A: Clinical data suggest that some specialized formulations, such as those where the active ingredient is already dissolved in a liquid or formulated as a sodium salt, may be absorbed faster than standard tablets, which can potentially lead to a faster reported onset of action.

How should Multidol be stored and disposed of?

How to Store and Dispose of Multidol (Ibuprofen)

Official regulatory documents define strict conditions for storing and discarding Multidol to ensure product stability and safety.

Required Storage Conditions

Condition Regulatory Requirement
Temperature Store at controlled room temperature, typically between 20°C and 25°C. Avoid excessive heat above 40°C and keep from freezing.
Protection Keep the medicine in a closed container, away from moisture and direct light. Store in the original package or a light-resistant container.
Child Safety Mandatory to keep the product out of the sight and reach of children and pets. Maintain the integrity of child-resistant packaging.

Disposal Instructions

Unused or expired Multidol must be disposed of in accordance with local requirements. The preferred method is using a drug take-back location. If unavailable, mix the medicine with an undesirable substance (such as dirt or coffee grounds), seal it in a container, and place it in the household trash. Do not flush Multidol down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Multidol found in:

A-Z Index: